Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
Details
Publication Year 2024-01,Volume 35,Issue #1,Page 98-106
Journal Title
Annals of Oncology
Publication Type
Research article
Abstract
BACKGROUND: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette-Guérin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations are commonly detected in NMIBC. We evaluated the activity of oral erdafitinib, a selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy in patients with high-risk NMIBC and select FGFR3/2 alterations following recurrence after BCG treatment. PATIENTS AND METHODS: Patients aged ≥18 years with recurrent, BCG-treated, papillary-only high-risk NMIBC (high-grade Ta/T1) and select FGFR alterations refusing or ineligible for radical cystectomy were randomized to 6 mg daily oral erdafitinib or investigator's choice of intravesical chemotherapy (mitomycin C or gemcitabine). The primary endpoint was recurrence-free survival (RFS). The key secondary endpoint was safety. RESULTS: Study enrollment was discontinued due to slow accrual. Seventy-three patients were randomized 2 : 1 to erdafitinib (n = 49) and chemotherapy (n = 24). Median follow-up for RFS was 13.4 months for both groups. Median RFS was not reached for erdafitinib [95% confidence interval (CI) 16.9 months-not estimable] and was 11.6 months (95% CI 6.4-20.1 months) for chemotherapy, with an estimated hazard ratio of 0.28 (95% CI 0.1-0.6; nominal P value = 0.0008). In this population, safety results were generally consistent with known profiles for erdafitinib and chemotherapy. CONCLUSIONS: Erdafitinib prolonged RFS compared with intravesical chemotherapy in patients with papillary-only, high-risk NMIBC harboring FGFR alterations who had disease recurrence after BCG therapy and refused or were ineligible for radical cystectomy.
Publisher
Elsevier
Keywords
Humans; Adolescent; Adult; BCG Vaccine/adverse effects; *Non-Muscle Invasive Bladder Neoplasms; Adjuvants, Immunologic/therapeutic use; Neoplasm Recurrence, Local/drug therapy; *Urinary Bladder Neoplasms; Neoplasm Invasiveness; *Pyrazoles; *Quinoxalines; Fgfr; erdafitinib; intravesical chemotherapy; non-muscle-invasive bladder cancer; recurrence-free survival; safety
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1016/j.annonc.2023.09.3116
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-01-30 06:27:04
Last Modified: 2024-01-30 06:27:34

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙